Company profile
Immage Biotherapeutics Corp.
OTC: IMMG · Financial Services · Financial - Conglomerates
PublicHQ Bethesda, Reports USD
#879 of 1,013 Financial Services companies by revenue
EA Score
——FH —DQ —GM —SS 16
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, disclosure history · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$216.5k
Employees
3
as of 2026-08-29
Market cap
$15.2k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02016
Net income-$216.5k-$216.5k2016
Operating income-$216.5k-$216.5k2016
Total assets$243.1k$243.1k2016
Liabilities$55.8k$55.8k2016
Equity$187.3k$187.3k2016
Revenue trend
FY2012 – FY2016 · USD
FY12
FY13
FY14
FY15
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Immage Biotherapeutics Corp.’s revenue?
Immage Biotherapeutics Corp. booked $0 in FY2016 revenue — among the slowest-growing Financial Services companies we track, at a -Infinity% net margin.
Peers · Financial Services
Bioethics, Ltd.——Sky440, Inc.——Crown Baus Capital Corp.——GreenBank Capital Inc.——Mapath Capital Corp——Kunekt Corporation——Key facts
CEOZhi Cong Mou
SectorFinancial Services
IndustryFinancial - Conglomerates
HeadquartersBethesda, null
ExchangeOTC: IMMG
Employees3
IPO date2022-12-02
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.